Posted by Hugh on February 10, 2022, at 13:11:42
In reply to Re: Psilocybin-cannabidiol combo for depression, posted by beckett2 on February 7, 2022, at 15:11:22
I hadn't thought of that. Could be.
> > I hope linkadge will chime in here, because I haven't tried agmatine, but I have been researching it since linkadge's post about it. Agmatine is an NMDA antagonist. It "site-selectively inhibits excessive NMDA activity without disrupting normal, physiological function," like ketamine can. It appears to be safe and effective.
> >
> > In a pilot study, 11 patients suffering from neuropathies took agmatine daily for 8 weeks. At the end of the 8 weeks, their pain levels were reduced an average of 46%. The dose used in this pilot study was 6 445-mg agmatine sulfate capsules per day (3 capsules twice daily, or 2 capsules thrice daily with or after meals).
> >
> > This 2017 thesis from the University of Minnesota has a lot of information about agmatine:
> >
> > https://conservancy.umn.edu/bitstream/handle/11299/193441/Peterson_umn_0130E_18748.pdf
>
> On a related topic, just thought since you and link are talking about glutamate. Do you wonder if a predictor of glutamate antagonist's sucess might be a combination of patients presenting with pain and depression?
>
>
poster:Hugh
thread:1118309
URL: http://www.dr-bob.org/babble/20220128/msgs/1118516.html